Abstract:Background: Glypican-3 (GPC3) is highly expressed in most of the hepatocellular carcinomas (HCCs), even in small HCCs. It may be used as a potential biomarker for early detection of HCC. The aptamer is a promising targeting agent with unique advantages over antibody. This study was to introduce a novel GPC3 specific aptamer (AP613-1), to verify its specific binding property in vitro, and to evaluate its targeting efficiency in vivo by performing near-infrared (NIR) fluorescence imaging on an HCC xenograft model. Methods: AP613-1 was generated from the systematic evolution of ligands by exponential enrichment. Flow cytometry and aptamer-based immunofluorescence imaging were performed to verify the binding affinity of AP613-1 to GPC3 in vitro. NIR Fluorescence images of nude mice with unilateral (n=12) and bilateral (n=4) subcutaneous xenograft tumors were obtained. Correlation between the tumor fluorescence intensities in vivo and ex vivo was analyzed. Results: AP613-1 could specifically bind to GPC3 in vitro. In vivo and ex vivo tumors, fluorescence intensities were in excellent correlation (P<0.001, r=0.968). The fluorescence intensity is significantly higher in tumors given Alexa Fluor 750 (AF750) labeled AP613-1 than in those given AF750 labeled initial ssDNA library both in vivo (P<0.001) and ex vivo (P=0.022). In the mice with bilateral subcutaneous tumors injected with AF750 labeled AP613-1, Huh-7 tumors showed significantly higher fluorescence intensities than A549 tumors both in vivo (P=0.016) and ex vivo (P=0.004). Conclusions: AP613-1 displays a specific binding affinity to GPC3 positive HCC. Fluorescently labeled AP613-1 could be used as an imaging probe to subcutaneous HCC in xenograft models.

THE FURTHER CHARACTERIZATION OF THE SPECIFICALLY BINDING PEPTIDE TO HEPATOCELLULAR CARCINOMA

Hepatocellular Carcinoma Detection by Cell Sensor Based on Anti-GPC3 Single-Chain Variable Fragment

The further characterization of the peptide specifically binding to gastric cancer

An update on bacterial meningitis.

Multi-modal Imaging for Uptake of Peptide Ligand Specific for CD44 by Hepatocellular Carcinoma

Identification of a Glypican-3 Binding Peptide From a Phage-Displayed Peptide Library for PET Imaging of Hepatocellular Carcinoma

An innovative peptide with high affinity to GPC3 for hepatocellular carcinoma diagnosis

CS2 activation at uranium(III) siloxide ate complexes: the effect of a Lewis acidic site.

In Vivo Fluorescence Imaging of Hepatocellular Carcinoma Using a Novel GPC3-specific Aptamer Probe

Identification of a peptide binding to cancer antigen Kita‐kyushu lung cancer antigen 1 from a phage‐display library

Subtractive Cell-SELEX Selection of DNA Aptamers Binding Specifically and Selectively to Hepatocellular Carcinoma Cells with High Metastatic Potential.

Screening and identification of a specific peptide binding to breast cancer cells from a phage-displayed peptide library

Leg edema: clinical clues to the differential diagnosis.

Identification of an aptamer through whole cell-SELEX for targeting high metastatic liver cancers.

Targeting of Hepatoma Cell and Suppression of Tumor Growth by A Novel 12mer Peptide Fused to Superantigen Tsst-1

[Effects of High Metastatic Potential Hepatocellular Carcinoma Cell-Binding Peptide on the Invasion and Metastasis of Liver Cancer].

Investigation of SP94 Peptide As a Specific Probe for Hepatocellular Carcinoma Imaging and Therapy

Screening and Verification of Ssdna Aptamers Targeting Human Hepatocellular Carcinoma

HER2 Targeting Peptides Screening and Applications in Tumor Imaging and Drug Delivery

A Sensitive Method for Protein Assays Using a Peptide-Based Nano-Label: Human Glypican-3 Detection for Hepatocellular Carcinomas Diagnosis.

Microarray Based Screening of Peptide Nano Probes for HER2 Positive Tumor.